WO2023170714A1 - A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases - Google Patents
A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases Download PDFInfo
- Publication number
- WO2023170714A1 WO2023170714A1 PCT/IN2023/050232 IN2023050232W WO2023170714A1 WO 2023170714 A1 WO2023170714 A1 WO 2023170714A1 IN 2023050232 W IN2023050232 W IN 2023050232W WO 2023170714 A1 WO2023170714 A1 WO 2023170714A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- skin
- foot
- eczema
- herbal composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 119
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 39
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 39
- 206010013786 Dry skin Diseases 0.000 title claims abstract description 30
- 230000037336 dry skin Effects 0.000 title claims abstract description 27
- 230000000699 topical effect Effects 0.000 title claims abstract description 27
- 208000031888 Mycoses Diseases 0.000 title claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 206010017533 Fungal infection Diseases 0.000 title claims abstract description 19
- 238000005336 cracking Methods 0.000 title claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 244000283207 Indigofera tinctoria Species 0.000 claims abstract description 17
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims abstract description 17
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 claims abstract description 17
- 239000003205 fragrance Substances 0.000 claims abstract description 15
- 239000003755 preservative agent Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000002335 preservative effect Effects 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 11
- 239000003921 oil Substances 0.000 claims abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 10
- 239000006286 aqueous extract Substances 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 26
- 239000006071 cream Substances 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 13
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 13
- 229960002216 methylparaben Drugs 0.000 claims description 13
- 239000010679 vetiver oil Substances 0.000 claims description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 239000000292 calcium oxide Substances 0.000 claims description 12
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 235000013871 bee wax Nutrition 0.000 claims description 8
- 239000012166 beeswax Substances 0.000 claims description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 8
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- CPRMKOQKXYSDML-UHFFFAOYSA-M rubidium hydroxide Chemical compound [OH-].[Rb+] CPRMKOQKXYSDML-UHFFFAOYSA-M 0.000 claims description 8
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- 235000019271 petrolatum Nutrition 0.000 claims description 5
- 229960004418 trolamine Drugs 0.000 claims description 5
- KOPBYBDAPCDYFK-UHFFFAOYSA-N Cs2O Inorganic materials [O-2].[Cs+].[Cs+] KOPBYBDAPCDYFK-UHFFFAOYSA-N 0.000 claims description 4
- FUJCRWPEOMXPAD-UHFFFAOYSA-N Li2O Inorganic materials [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 claims description 4
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims description 4
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Inorganic materials [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 4
- AKUNKIJLSDQFLS-UHFFFAOYSA-M dicesium;hydroxide Chemical compound [OH-].[Cs+].[Cs+] AKUNKIJLSDQFLS-UHFFFAOYSA-M 0.000 claims description 4
- XUCJHNOBJLKZNU-UHFFFAOYSA-M dilithium;hydroxide Chemical compound [Li+].[Li+].[OH-] XUCJHNOBJLKZNU-UHFFFAOYSA-M 0.000 claims description 4
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 4
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- NOTVAPJNGZMVSD-UHFFFAOYSA-N potassium monoxide Inorganic materials [K]O[K] NOTVAPJNGZMVSD-UHFFFAOYSA-N 0.000 claims description 4
- 229910000026 rubidium carbonate Inorganic materials 0.000 claims description 4
- WPFGFHJALYCVMO-UHFFFAOYSA-L rubidium carbonate Chemical compound [Rb+].[Rb+].[O-]C([O-])=O WPFGFHJALYCVMO-UHFFFAOYSA-L 0.000 claims description 4
- 229910001953 rubidium(I) oxide Inorganic materials 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- IATRAKWUXMZMIY-UHFFFAOYSA-N strontium oxide Inorganic materials [O-2].[Sr+2] IATRAKWUXMZMIY-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 3
- 240000005385 Jasminum sambac Species 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 229910021538 borax Inorganic materials 0.000 claims description 3
- 229940067596 butylparaben Drugs 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 239000004328 sodium tetraborate Substances 0.000 claims description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 3
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 claims description 2
- 239000010656 jasmine oil Substances 0.000 claims description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 2
- 239000010671 sandalwood oil Substances 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 74
- 210000002683 foot Anatomy 0.000 description 37
- 208000003251 Pruritus Diseases 0.000 description 13
- 230000007803 itching Effects 0.000 description 10
- 208000010201 Exanthema Diseases 0.000 description 7
- 208000002474 Tinea Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 201000005884 exanthem Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 206010037844 rash Diseases 0.000 description 7
- 239000003246 corticosteroid Substances 0.000 description 6
- 206010020649 Hyperkeratosis Diseases 0.000 description 5
- 206010043870 Tinea infections Diseases 0.000 description 5
- 206010047571 Visual impairment Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000020312 Thickened skin Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000893966 Trichophyton verrucosum Species 0.000 description 3
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 206010005913 Body tinea Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 208000031439 Striae Distensae Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 201000003875 tinea corporis Diseases 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 206010017543 Fungal skin infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Definitions
- the present invention relates to an herbal composition for treating fungal, scaling, foot-crack, eczema and dry skin diseases made from non-toxic ingredients.
- the herbal composition may also be useful in treating psoriasis, foot com disease and the like.
- the skin acts as an effective barrier to maintain a dynamic equilibrium between the body and the environment. Skin also prevents invasion of pathogens, chemical and physical assaults, as well as the unregulated loss of water and solute from the body.
- Dry skin is a skin condition characterised by a lack of appropriate amount of water in the skin's epidermis. During drying of the skin, the corneous layer prematurely flakes away and cracks and scaling develop on the skin surface.
- Foot crack disease In foot crack disease, the sensitive skin on the bottom of the feet becomes too dry and may split open, causing painful cracks. These cracks may lead to pain during walking and can lead to serious infections. These cracks can become more severe and may even lead to bleeding. Foot crack disease can occur by cold and low humidity weather, dehydration, taking very hot bath showers etc.
- Scaling of skin may be a symptom of many medical conditions, including psoriasis, eczema, and fungal skin infections. In severe cases of scaling, the skin may break and may become vulnerable to bacterial, viral, and fungal infections, which can lead to other health complications as well.
- Eczema is a disease, which causes the skin to become itchy and red. It is common in children but can arise at any age. Eczema harms the skin barrier function. It also causes the skin to be more sensitive to various infections. Major symptoms of eczema include itching, red rashes, bumps and scaly, leathery patches of skin. The causes of the eczema are not well understood and is thought to be caused by a disorder of the immune system and appears to have an interplay between genetic and environmental factors. Currently there is no cure for eczema. In severe cases of infection, anti-inflammatory corticosteroids like prednisone or cortisone are used and they usually cause stretch marks, eye damage and thinning of skin. Antihistamines are generally prescribed to reduce the itching associated with eczema.
- Tinea is a group of skin infections, caused by fungus; examples include tinea corporis (ringworm), tinea pedis. In ringworm infection, no worm is involved and gets its name because of its appearance. Tinea is a superficial skin infection that may affect any part of human body, including the face, hands, feet, scalp, beard etc. It usually appears as a red, itchy, circular rash with clearer skin in the middle. Ringworm is very contagious, and people can get the infection by direct contact and also by indirect contact through an infected person's clothing or even by touching any object that has contacted an infected person's skin. Mild infections may be cured by antifungal medications applied on the skin externally.
- Corticosteroids are used for tinea corporis treatments.
- prolonged use of steroids can lead to persistent and recurrent infections and can have adverse effects on the skin such as skin atrophy, stretch marks and threadlike red lines or patterns on the skin.
- Foot coms and calluses are potentially painful conditions that form thickened skin areas. While com occurs in a thick and localized area, that usually has a conical or circular shape. Callus occurs in more diffused and flattened area of the skin. Coms and calluses may occur on any part of the feet and sometimes on the fingers also. Coms are often very painful and may lead to difficulty in walking. Com is caused by repeated mechanical trauma due to pressure forces or fiction. Treatment for coms and calluses usually involves the removal of excess skin by trimming or applying callus-removing medication such as salicylic acid. The conventional method of treating coms involves surgery. However, it is not a permanent solution, as coms recur frequently. Thus, all these treatments give only temporary cure.
- the present invention relates to a topical herbal composition
- a topical herbal composition comprising 1 to 5 parts by weight of a mixture comprising 80 wt% to 99.9 wt% of dried Indigofera tinctoria leaves powder or aqueous extract, 0. lwt% to 20 wt % of a base or a mixture of two or more bases, and 1 to 10 parts by weight of water.
- the base(s) may be selected from the group comprising of CaO, MgO, SrO, BaO, Li 2 O, Na 2 O, K 2 O, Rb 2 O, Cs 2 O, LiOH, NaOH, KOH, RbOH, CsOH, Li 2 CO3, Na 2 CO 3 , K 2 CO 3 , Rb 2 CO 3 and Cs 2 CO 3 .
- composition can further comprise of 10 wt% to 40 wt% of a pharmaceutically acceptable excipients, 0.01wt%-0.3 wt% of a preservative, 0. 1 wt% to lwt% of a fragrance oil, 3 wt% to 8 wt% of an emulsifying agent.
- the pharmaceutically acceptable excipient can be selected from glycerol, petroleum jelly, or beeswax
- the preservative can be selected from methyl paraben, butylparaben, ethylparaben, propylparaben
- the fragrance oil can selected from be vetiver oil, lavender oil, lemongrass oil, jasmine, or sandalwood oil
- the emulsifying agent can selected from triethanol amine, beeswax, borax, lecithin, gum arabic, gelatin, or cholesterol.
- the topical composition can be an ointment, a paste, or a cream.
- the topical herbal composition can comprise of 2.5 parts by weight of the mixture of dried Indigofera tinctoria leaves powder or aqueous extract and CaO powder in a weight ratio of 97.5:2.5, and 5.5 parts by weight of water.
- the composition can further comprise of 3.0 wt% of glycerol, 1.0 wt% of vetiver oil and 0.1 wt % of methyl paraben.
- the topical composition can be for treating skin ailments selected from dry skin, footcracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like.
- the present invention also relates to a method of treating skin ailments selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like by applying the composition on the affected area for 3 to 5 days.
- Figure 1 shows the before and after images of applying the herbal topical composition on foot cracking.
- Fig 1(a) shows the photograph of the cracked foot before application and
- Fig 1(b) shows the photograph of the foot after the application of the composition for 3 to 4 consecutive days.
- Fig. 1(b) shows that the dry and thickened skin was found to be completely removed and natural skin was restored.
- Figure 2 shows before and after images of applying the herbal topical composition on a patient with Eczema.
- Fig. 2(a) shows the photograph of an Eczema patient having severe red rashes, bumps, scaly patches at the back of the neck before application of the composition and
- Fig. 2(b) shows the photograph of the skin after application of the composition for 2-3 consecutive days.
- Fig 2(b) shows that the itching, red rashes, bumps on the skin and scaly, leathery patches of skin associated with eczema were completely cured and natural skin was restored after applying the composition for 2-3 days.
- Figure 3 shows the before and after images of applying the herbal topical composition on a patient with Fungal infection.
- Fig 3(a) shows photograph of the patient’s skin affected with fungal infection before application and
- Fig. 3(b) clearly shows the reduction in itching, redness, scaling and the inflammation associated with the tinea infections after application of the composition two times per day for 3-4 days.
- the aim of the present invention is to formulate an herbal composition that can be used for treating various skin conditions such as fungal infection, foot-cracking, scaling, eczema and dry skin diseases using non-toxic ingredients.
- the herbal composition may also be useful in treating psoriasis, foot com disease and the like.
- the present invention provides a topical herbal composition comprising about 1 to 5 parts by weight of a mixture comprising 80wt% to 99.9 wt% of dried Indigofera tinctoria leaves powder and 0.1wt% to 20 wt% of a base or a mixture of two or more bases, and 1 to 10 parts by weight of water.
- the present invention provides a topical herbal composition comprising about 1 to 5 parts by weight of a mixture comprising 80wt% to 99.9 wt% of dried Indigofera tinctoria leaf aqueous extract and 0.1wt% to 20 wt% of a base or a mixture of two or more bases, and 1 to 10 parts by weight of water.
- the base(s) in the composition can be selected from the following group comprising of MgO, CaO, SrO, BaO, Li 2 O, Na 2 O, K 2 O, Rb 2 O, Cs 2 O, LiOH, NaOH, KOH, RbOH, CsOH, Li 2 CO 3 , Na 2 CO 3 , K 2 CO 3 , Rb 2 CO 3 and Cs 2 CO 3 or a combination thereof.
- the base can be CaO.
- the composition of the present invention comprising dried Indigofera tinctoria and a base can be effective in treating various skin conditions such as foot cracking, scaling, eczema, dry skin disease and fungal infection.
- Figures 1 to 3 demonstrate the efficacy of the composition in said skin conditions. It was found that Indigofera tinctoria when used alone with water and without the base such as CaO did not provide such a result. Therefore, Indigofera tinctoria and the base synergistically treats the said skin conditions such as dry skin, eczema, foot cracking and scaling. It was observed that the said conditions did not recur even after 6 months of the treatment using the composition of the present invention.
- the composition of the present invention synergistically treats more than one skin ailments and obviates the need of using different products.
- a patient is required to use a dry skin treatment cream and a corticosteroid.
- the composition of the present invention synergistically treats eczema with one paste or cream treatment and obviates the need of using steroids such as corticosteroid.
- composition of the present invention also alleviates the symptoms and restore the normal skin in a short period of time.
- the composition shows effective results in 3 to 6 days for various skin ailments such as eczema, fungal disease, and dry skin.
- the herbal topical composition can be a cream or an ointment.
- the composition can be used as such without any further pharmaceutical excipient.
- the herbal composition can also be made in cream form by mixing the paste form with desired weight ratio of the composition along with a cream base.
- the cream base can be formulated with variety of pharmaceutically acceptable excipient, oils, preservatives, fragrance oils and emulsifying agents known in the art.
- the composition can optionally further comprise 10 wt% to 40 wt% of a pharmaceutically acceptable excipient, 0.01wt%-0.3 wt% of a preservative, 0. lwt% to lwt% of a fragrance oil, and/or 3wt% to 8 wt% of an emulsifying agent.
- the pharmaceutically acceptable excipient can be selected from glycerol, petroleum jelly, or beeswax.
- the preservative can be selected from methyl paraben, butylparaben, ethylparaben, propylparaben, etc.
- the fragrance oil can be selected from vetiver oil, lavender, lemongrass, jasmine, sandalwood, etc.
- the emulsifying agent can be selected from triethanol amine, beeswax, borax, lecithin, gum Arabic, gelatin, cholesterol, etc.
- composition of the present invention can be prepared by methods known in the art to form a cream or paste composition.
- composition in paste form can further be mixed with a 20 wt%- 40 wt% of a pharmaceutically acceptable excipient such as petroleum jelly, a 0.01wt%-0.3 wt% of preservative such as methyl paraben and a 0.1 wt%-lwt% of a fragrance oil such as vetiver oil to form a cream.
- a pharmaceutically acceptable excipient such as petroleum jelly
- preservative such as methyl paraben
- fragrance oil such as vetiver oil
- the composition in paste form can further be mixed with 20 wt% - 40 wt% of pharmaceutically acceptable excipients such as glycerol, 2 wt% -6 wt% of a beeswax, 3wt%-8 wt% of an emulsifier such as triethanol amine, 0.01wt%-0.3 wt% of a preservative such as methyl paraben and 0.1wt%-lwt% of a fragrance oil such as vetiver oil to form cream.
- pharmaceutically acceptable excipients such as glycerol, 2 wt% -6 wt% of a beeswax, 3wt%-8 wt% of an emulsifier such as triethanol amine, 0.01wt%-0.3 wt% of a preservative such as methyl paraben and 0.1wt%-lwt% of a fragrance oil such as vetiver oil to form cream.
- the topical composition comprises 2.5 parts by weight of the mixture of dried Indigofera tinctoria leaves powder or aqueous extract and CaO powder in a weight ratio of 97.5:2.5, and 5.5 parts by weight of water.
- the composition can be in the form of a paste.
- the composition may optionally further comprise of 3.0 wt% of glycerol, 1.0 wt% of vetiver oil and 0.1 wt% of methyl paraben to form a cream.
- the present invention also relates to a composition for use in the treatment of skin conditions selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like.
- the present invention also relates to a method of treating skin conditions selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like by applying the composition of the present invention topically on the affected area.
- the method includes applying the composition of the present invention topically on the affected area of dry skin 1 or 2 times per day for 3 to 4 days.
- the dry skin condition was completely cured, and natural and supple skin were found to be restored. Dry skin condition did not recur for at least 6 months.
- a method of treating cracks in the foot comprising cleaning the foot with soap and soaking the cracked foot in lukewarm salt water for about 15 minutes, and allowing the foot to dry. Applying the composition of the present invention on the affected areas of the foot and keeping the foot undisturbed for 30 to 60 minutes. The method is repeated for 3 to 4 consecutive days. The dry and thickened skin was found to be completely removed.
- Figure 1(a) and 1(b) shows the before and after images of foot cracking respectively upon applying the composition of the present invention.
- a method of treating scaling of skin comprising applying the composition of the present invention to the affected areas of the foot of the patient 2 times per day for one week.
- the flakes sticking to the skin were found to be peeled off. Itching and redness were healed and smooth skin appeared within 3-4 days.
- a method for treating Eczema in a patient with the topical composition of the present invention includes applying the composition of the present invention to the affected area of skin of the patient 2 times per day for 2-3 days.
- the itching, red rashes, bumps on the skin and scaly, leathery patches of skin associated with eczema were completely cured and natural and supple skin was restored.
- Fig.2(a) shows image of the affected skin of Eczema patient before application of the composition and
- Fig. 2(b) shows that symptoms associated with eczema were completely cured, and natural skin was restored upon application of the composition for 2-3 consecutive days.
- a method of treating fungal infections in a patient with the topical composition of the present invention includes applying the topical composition to the affected area of skin, having characteristics of tinea infections two times per day for 3-4 consecutive days.
- Fig. 3(a) shows image of the skin affected with fungal infection before the application and Fig.3(b) shows that after application of the composition for 3-4 days, the itching, redness, scaling, inflammation associated with tinea infection were completely healed and smooth skin was restored.
- the topical composition of the present invention can be made from non-toxic and herbal ingredients and was found not to have any side effects.
- the composition was found to be very effective in restoring the normal and supple skin.
- the composition was found to give permanent/long term cure even within 3-5 times of topical application for the skin problems such as scaling, dry skin, foot cracking, eczema etc.
- eczema currently no satisfactory cure currently available and the doctors prescribe several medications to alleviate the symptoms of eczema.
- These include corticosteroid creams and ointments, antiinflammatory medications to relieve inflammation and itchiness.
- the corticosteroid creams have potential side effects and are not safe to use.
- the composition of the present invention can therefore be a safe, effective, natural and cheap alternative for the existing treatments for skin ailments such as scaling, dry skin, foot cracks and eczema.
- the paste obtained in example 5 (8.0 g) was mixed with 3.0 g of glycerol to form a cream. Then 1.0 g of vetiver oil was added to give fragrance and 0. 1 g of methyl paraben was added as preservative. This composition was stored closed vessels and was found to be stable for at least 6 months. The cream was applied on the affected area of skin.
- Paste obtained in example 1 (8.0 g) is mixed with 5.0 g of glycerol, 0.6 g of beeswax and 1.0 g of triethanol amine as emulsifier, 1.0 g of vetiver oil (to give fragrance) and 0.2 g of methyl paraben (added as preservative).
- This composition was stored closed vessels and was found to be stable for at least 6 months.
- compositions given in example 1-8 and as a control only Indigofera tinctoria leaf powder was mixed with water were applied to the affected skin areas of various patients suffering from skin ailments such as dry skin, foot-cracking, scaling, eczema and fungal infections.
- skin ailments such as dry skin, foot-cracking, scaling, eczema and fungal infections.
- results, after application of the skin compositions, are summarized below.
- Treatment of Dry skin The composition given in examples 1 to 8 was applied 1 or 2 times a day on the affected area of dry skin on patient for 3 to 4 days.
- Table 1 It was observed that the dry skin condition was completely cured and natural and supple skin were found to be restored on treating with the composition of Examples 1 to 8.
- Treatment of Foot cracking The affected foot was thoroughly cleaned with soap and soaked in lukewarm salt water for about 15 minutes and allowed to dry. Then the composition given in example 1 to 8 was applied in the affected areas of the foot and some of the surrounding areas for 3-4 consecutive days. Then the foot was kept undisturbed for 30 to 60 minutes.
- FIG. 1 shows the before and after images of foot cracking upon applying the composition.
- the natural and supple skin was restored and foot crack did not recur at least for one year upon treating with composition of
- FIG. 2(a) is a photograph of an Eczema patient with severe red rashes, bumps, scales on the back of the neck before applying the composition
- Fig 2(b) is the photograph of the skin after applying the composition on the affected area 2 times per day for 2-3 days. It was observed that the itching, red rashes, bumps on the skin and scaly, leathery patches of skin associated with eczema were found to be cured and natural and supple skin was restored upon application of the composition in Examples 1-8.
- Treatment of Fungal infection The composition given in examples 1-8 were applied to the affected area of skin, showing the characteristics of tinea infections, two times per day for 3-4 days.
- compositions of Examples 1-8 were effective in reducing the itching, redness, scaling and the inflammation associated with the tinea infections.
- the Figure 3(a) and 3(b) shows the photographs before and after applying the composition on a patient with fungal infections respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to topical herbal composition comprising 1 to 5 parts by weight of a mixture comprising 80 wt% to 99.9 wt% of dried Indigofera tinctoria leaves powder or aqueous extract and 0.1wt% to 20 wt% of a base or a mixture of two or more bases, and 1 to 10 parts by weight of water. The composition optionally comprises 10 wt% to 40 wt% of a pharmaceutically acceptable excipient, 0.01wt%-0.3 wt% of preservative, 0.1wt% to 1wt% fragrance oil, and 3wt% to 8 wt% of emulsifying agent. The invention also relates to a method of treating skin ailments selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot corn disease or the like by applying the composition on the affected area for 3 to 5 days.
Description
A TOPICAL HERBAL COMPOSITION FOR FUNGAL INFECTION, SCALING, FOOT CRACKING, ECZEMA AND DRY SKIN DISEASES
FIELD OF INVENTION
The present invention relates to an herbal composition for treating fungal, scaling, foot-crack, eczema and dry skin diseases made from non-toxic ingredients. The herbal composition may also be useful in treating psoriasis, foot com disease and the like.
BACKGROUND OF THE INVENTION
The skin acts as an effective barrier to maintain a dynamic equilibrium between the body and the environment. Skin also prevents invasion of pathogens, chemical and physical assaults, as well as the unregulated loss of water and solute from the body.
Dry skin is a skin condition characterised by a lack of appropriate amount of water in the skin's epidermis. During drying of the skin, the corneous layer prematurely flakes away and cracks and scaling develop on the skin surface.
In foot crack disease, the sensitive skin on the bottom of the feet becomes too dry and may split open, causing painful cracks. These cracks may lead to pain during walking and can lead to serious infections. These cracks can become more severe and may even lead to bleeding. Foot crack disease can occur by cold and low humidity weather, dehydration, taking very hot bath showers etc.
In skin scaling, the outer layer of the epidermis is lost as large, scale-like flakes. The scales can itch and redden, and it may occur in the hands, feet, face etc. affecting the quality of life. Scaling of skin may be a symptom of many medical conditions, including psoriasis, eczema, and fungal skin infections. In severe cases of scaling, the skin may break and may become vulnerable to bacterial, viral, and fungal infections, which can lead to other health complications as well.
Eczema is a disease, which causes the skin to become itchy and red. It is common in children but can arise at any age. Eczema harms the skin barrier function. It also causes the skin to be more sensitive to various infections. Major symptoms of eczema include itching,
red rashes, bumps and scaly, leathery patches of skin. The causes of the eczema are not well understood and is thought to be caused by a disorder of the immune system and appears to have an interplay between genetic and environmental factors. Currently there is no cure for eczema. In severe cases of infection, anti-inflammatory corticosteroids like prednisone or cortisone are used and they usually cause stretch marks, eye damage and thinning of skin. Antihistamines are generally prescribed to reduce the itching associated with eczema.
Tinea is a group of skin infections, caused by fungus; examples include tinea corporis (ringworm), tinea pedis. In ringworm infection, no worm is involved and gets its name because of its appearance. Tinea is a superficial skin infection that may affect any part of human body, including the face, hands, feet, scalp, beard etc. It usually appears as a red, itchy, circular rash with clearer skin in the middle. Ringworm is very contagious, and people can get the infection by direct contact and also by indirect contact through an infected person's clothing or even by touching any object that has contacted an infected person's skin. Mild infections may be cured by antifungal medications applied on the skin externally. In severe infections, an infected person may need to take antifungal pills for several weeks. Corticosteroids are used for tinea corporis treatments. However, prolonged use of steroids can lead to persistent and recurrent infections and can have adverse effects on the skin such as skin atrophy, stretch marks and threadlike red lines or patterns on the skin.
Foot coms and calluses are potentially painful conditions that form thickened skin areas. While com occurs in a thick and localized area, that usually has a conical or circular shape. Callus occurs in more diffused and flattened area of the skin. Coms and calluses may occur on any part of the feet and sometimes on the fingers also. Coms are often very painful and may lead to difficulty in walking. Com is caused by repeated mechanical trauma due to pressure forces or fiction. Treatment for coms and calluses usually involves the removal of excess skin by trimming or applying callus-removing medication such as salicylic acid. The conventional method of treating coms involves surgery. However, it is not a permanent solution, as coms recur frequently. Thus, all these treatments give only temporary cure.
Now-a-days consumers increasingly seek natural, non-toxic and eco-friendly ingredients in skin medicine, which does not have any side effects on the skin. Most of the currently available treatment methods for above mentioned skin diseases have many
limitations and hence it is very pertinent to develop a skin medicine from non-toxic and environmentally friendly ingredients.
SUMMARY OF THE INVENTION
The present invention relates to a topical herbal composition comprising 1 to 5 parts by weight of a mixture comprising 80 wt% to 99.9 wt% of dried Indigofera tinctoria leaves powder or aqueous extract, 0. lwt% to 20 wt % of a base or a mixture of two or more bases, and 1 to 10 parts by weight of water.
The base(s) may be selected from the group comprising of CaO, MgO, SrO, BaO, Li2O, Na2O, K2O, Rb2O, Cs2O, LiOH, NaOH, KOH, RbOH, CsOH, Li2CO3, Na2CO3, K2CO3, Rb2CO3 and Cs2CO3.
The composition can further comprise of 10 wt% to 40 wt% of a pharmaceutically acceptable excipients, 0.01wt%-0.3 wt% of a preservative, 0. 1 wt% to lwt% of a fragrance oil, 3 wt% to 8 wt% of an emulsifying agent.
The pharmaceutically acceptable excipient can be selected from glycerol, petroleum jelly, or beeswax, the preservative can be selected from methyl paraben, butylparaben, ethylparaben, propylparaben, the fragrance oil can selected from be vetiver oil, lavender oil, lemongrass oil, jasmine, or sandalwood oil, the emulsifying agent can selected from triethanol amine, beeswax, borax, lecithin, gum arabic, gelatin, or cholesterol. The topical composition can be an ointment, a paste, or a cream.
The topical herbal composition can comprise of 2.5 parts by weight of the mixture of dried Indigofera tinctoria leaves powder or aqueous extract and CaO powder in a weight ratio of 97.5:2.5, and 5.5 parts by weight of water. The composition can further comprise of 3.0 wt% of glycerol, 1.0 wt% of vetiver oil and 0.1 wt % of methyl paraben.
The topical composition can be for treating skin ailments selected from dry skin, footcracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like.
The present invention also relates to a method of treating skin ailments selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like by applying the composition on the affected area for 3 to 5 days.
BRIEF DESCRIPTION OF DRAWING
Figure 1 shows the before and after images of applying the herbal topical composition on foot cracking. Fig 1(a) shows the photograph of the cracked foot before application and Fig 1(b) shows the photograph of the foot after the application of the composition for 3 to 4 consecutive days. Fig. 1(b) shows that the dry and thickened skin was found to be completely removed and natural skin was restored.
Figure 2 shows before and after images of applying the herbal topical composition on a patient with Eczema. Fig. 2(a) shows the photograph of an Eczema patient having severe red rashes, bumps, scaly patches at the back of the neck before application of the composition and Fig. 2(b) shows the photograph of the skin after application of the composition for 2-3 consecutive days. Fig 2(b) shows that the itching, red rashes, bumps on the skin and scaly, leathery patches of skin associated with eczema were completely cured and natural skin was restored after applying the composition for 2-3 days.
Figure 3 shows the before and after images of applying the herbal topical composition on a patient with Fungal infection. Fig 3(a) shows photograph of the patient’s skin affected with fungal infection before application and Fig. 3(b) clearly shows the reduction in itching, redness, scaling and the inflammation associated with the tinea infections after application of the composition two times per day for 3-4 days.
DETAILED DESCRIPTION OF INVENTION
The aim of the present invention is to formulate an herbal composition that can be used for treating various skin conditions such as fungal infection, foot-cracking, scaling, eczema and dry skin diseases using non-toxic ingredients. The herbal composition may also be useful in treating psoriasis, foot com disease and the like.
In an embodiment, the present invention provides a topical herbal composition comprising about 1 to 5 parts by weight of a mixture comprising 80wt% to 99.9 wt% of dried Indigofera tinctoria leaves powder and 0.1wt% to 20 wt% of a base or a mixture of two or more bases, and 1 to 10 parts by weight of water.
In an embodiment, the present invention provides a topical herbal composition comprising about 1 to 5 parts by weight of a mixture comprising 80wt% to 99.9 wt% of dried Indigofera
tinctoria leaf aqueous extract and 0.1wt% to 20 wt% of a base or a mixture of two or more bases, and 1 to 10 parts by weight of water.
The base(s) in the composition can be selected from the following group comprising of MgO, CaO, SrO, BaO, Li2O, Na2O, K2O, Rb2O, Cs2O, LiOH, NaOH, KOH, RbOH, CsOH, Li2CO3, Na2CO3, K2CO3, Rb2CO3 and Cs2CO3 or a combination thereof. Preferably, the base can be CaO.
The composition of the present invention comprising dried Indigofera tinctoria and a base can be effective in treating various skin conditions such as foot cracking, scaling, eczema, dry skin disease and fungal infection. Figures 1 to 3 demonstrate the efficacy of the composition in said skin conditions. It was found that Indigofera tinctoria when used alone with water and without the base such as CaO did not provide such a result. Therefore, Indigofera tinctoria and the base synergistically treats the said skin conditions such as dry skin, eczema, foot cracking and scaling. It was observed that the said conditions did not recur even after 6 months of the treatment using the composition of the present invention. Thus, the composition of the present invention synergistically treats more than one skin ailments and obviates the need of using different products. For example, typically, for the treatment of eczema, a patient is required to use a dry skin treatment cream and a corticosteroid. The composition of the present invention synergistically treats eczema with one paste or cream treatment and obviates the need of using steroids such as corticosteroid.
The composition of the present invention also alleviates the symptoms and restore the normal skin in a short period of time. The composition shows effective results in 3 to 6 days for various skin ailments such as eczema, fungal disease, and dry skin.
In another embodiment, the herbal topical composition can be a cream or an ointment. The composition can be used as such without any further pharmaceutical excipient. However, the herbal composition can also be made in cream form by mixing the paste form with desired weight ratio of the composition along with a cream base. The cream base can be formulated with variety of pharmaceutically acceptable excipient, oils, preservatives, fragrance oils and emulsifying agents known in the art.
The composition can optionally further comprise 10 wt% to 40 wt% of a pharmaceutically acceptable excipient, 0.01wt%-0.3 wt% of a preservative, 0. lwt% to lwt% of a fragrance oil,
and/or 3wt% to 8 wt% of an emulsifying agent. The pharmaceutically acceptable excipient can be selected from glycerol, petroleum jelly, or beeswax. The preservative can be selected from methyl paraben, butylparaben, ethylparaben, propylparaben, etc. The fragrance oil can be selected from vetiver oil, lavender, lemongrass, jasmine, sandalwood, etc. The emulsifying agent can be selected from triethanol amine, beeswax, borax, lecithin, gum Arabic, gelatin, cholesterol, etc.
The composition of the present invention can be prepared by methods known in the art to form a cream or paste composition.
In another embodiment, the composition in paste form can further be mixed with a 20 wt%- 40 wt% of a pharmaceutically acceptable excipient such as petroleum jelly, a 0.01wt%-0.3 wt% of preservative such as methyl paraben and a 0.1 wt%-lwt% of a fragrance oil such as vetiver oil to form a cream.
In another embodiment, the composition in paste form can further be mixed with 20 wt% - 40 wt% of pharmaceutically acceptable excipients such as glycerol, 2 wt% -6 wt% of a beeswax, 3wt%-8 wt% of an emulsifier such as triethanol amine, 0.01wt%-0.3 wt% of a preservative such as methyl paraben and 0.1wt%-lwt% of a fragrance oil such as vetiver oil to form cream.
In a preferred embodiment, the topical composition comprises 2.5 parts by weight of the mixture of dried Indigofera tinctoria leaves powder or aqueous extract and CaO powder in a weight ratio of 97.5:2.5, and 5.5 parts by weight of water. In an embodiment, the composition can be in the form of a paste. The composition may optionally further comprise of 3.0 wt% of glycerol, 1.0 wt% of vetiver oil and 0.1 wt% of methyl paraben to form a cream.
The present invention also relates to a composition for use in the treatment of skin conditions selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like.
The present invention also relates to a method of treating skin conditions selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like by applying the composition of the present invention topically on the affected area. The
method includes applying the composition of the present invention topically on the affected area of dry skin 1 or 2 times per day for 3 to 4 days. The dry skin condition was completely cured, and natural and supple skin were found to be restored. Dry skin condition did not recur for at least 6 months.
In another embodiment, a method of treating cracks in the foot comprising cleaning the foot with soap and soaking the cracked foot in lukewarm salt water for about 15 minutes, and allowing the foot to dry. Applying the composition of the present invention on the affected areas of the foot and keeping the foot undisturbed for 30 to 60 minutes. The method is repeated for 3 to 4 consecutive days. The dry and thickened skin was found to be completely removed. Figure 1(a) and 1(b) shows the before and after images of foot cracking respectively upon applying the composition of the present invention.
In a further embodiment, a method of treating scaling of skin comprising applying the composition of the present invention to the affected areas of the foot of the patient 2 times per day for one week. The flakes sticking to the skin were found to be peeled off. Itching and redness were healed and smooth skin appeared within 3-4 days.
In a further embodiment, a method for treating Eczema in a patient with the topical composition of the present invention is disclosed. The method includes applying the composition of the present invention to the affected area of skin of the patient 2 times per day for 2-3 days. The itching, red rashes, bumps on the skin and scaly, leathery patches of skin associated with eczema were completely cured and natural and supple skin was restored. Fig.2(a) shows image of the affected skin of Eczema patient before application of the composition and Fig. 2(b) shows that symptoms associated with eczema were completely cured, and natural skin was restored upon application of the composition for 2-3 consecutive days.
In further embodiment, a method of treating fungal infections in a patient with the topical composition of the present invention is disclosed. The method includes applying the topical composition to the affected area of skin, having characteristics of tinea infections two times per day for 3-4 consecutive days. Fig. 3(a) shows image of the skin affected with fungal infection before the application and Fig.3(b) shows that after application of the composition
for 3-4 days, the itching, redness, scaling, inflammation associated with tinea infection were completely healed and smooth skin was restored.
The topical composition of the present invention can be made from non-toxic and herbal ingredients and was found not to have any side effects. The composition was found to be very effective in restoring the normal and supple skin. The composition was found to give permanent/long term cure even within 3-5 times of topical application for the skin problems such as scaling, dry skin, foot cracking, eczema etc. In the case of eczema currently no satisfactory cure currently available and the doctors prescribe several medications to alleviate the symptoms of eczema. These include corticosteroid creams and ointments, antiinflammatory medications to relieve inflammation and itchiness. The corticosteroid creams have potential side effects and are not safe to use. The composition of the present invention can therefore be a safe, effective, natural and cheap alternative for the existing treatments for skin ailments such as scaling, dry skin, foot cracks and eczema.
EXAMPLES
The invention is furth er illustrated herein by mean of examples. The following examples are given by way of illustration only and therefore should not be constructed to limit the scope of the present invention.
The invention is illustrated with the help of following examples.
EXAMPLE 1
97.5 g of dried indigofera tinctoria leaves powder was mixed with 2.5 g of CaO powder (in the weight ratio 97.5:2.5). This mixture was stored in tight and dark vessels to prevent the entry of air and light. To 2.5 g of the above mixture was taken and was mixed with 5.5 g of demineralised water to form a paste. The paste is applied on the affected area of skin.
EXAMPLE 2
2.5 g of the mixture of dried indigofera tinctoria leaves powder and CaO powder (in the weight ratio 97.5:2.5) was mixed with 5.5 g of demineralised water to form a paste. This paste was then mixed with 3.0 g of glycerol to form a cream. Then 1.0 g of vetiver oil was added to give fragrance and 0.1g of methyl paraben was added as preservative. This
composition was stored closed vessels and was found to be stable for at least 6 months. The cream was applied on the affected area of the skin.
EXAMPLE 3
95.0 g of dried indigofera tinctoria leaves powder was mixed with 5.0 g of MgO powder (in the weight ratio 95.0:5.0). This mixture was stored in tight and dark vessels to prevent the entry of air and light. 2.5 g of the above mixture was taken and was mixed with 6.0 g of demineralised water to form a paste. The paste was applied on the affected area of the skin.
EXAMPLE 4
2.5 g of the mixture (indigofera tinctoria leaves powder and CaO powder) obtained in example 3 was mixed with 5.5 g of demineralised water to form a paste. To the paste 3.0 g of glycerol was added to form a cream. Then 1.0 g of vetiver oil was added to give fragrance and 0.1g of methyl paraben was added as preservative. This composition was stored closed vessels and was found to be stable for at least 6 months. The cream was applied on the affected area of the skin.
EXAMPLE 5
About 0.1 g NaOH was mixed well with 9.99 g of the dried Indigofera tinctoria leaves powder. This mixture was stored in tight and dark vessels to prevent the entry of air and light. 2.5 g of above mixture was taken and mixed with 5.0 g of demineralised water to form a paste. The paste was applied on the affected area of dry skin.
EXAMPLE 6
The paste obtained in example 5 (8.0 g) was mixed with 3.0 g of glycerol to form a cream. Then 1.0 g of vetiver oil was added to give fragrance and 0. 1 g of methyl paraben was added as preservative. This composition was stored closed vessels and was found to be stable for at least 6 months. The cream was applied on the affected area of skin.
EXAMPLE 7
The paste obtained in example 1 (8.0 g) is mixed with 4.28 g of petroleum jelly, 0.5 g of vetiver oil (to give fragrance) and 0.2 g of methyl paraben (added as preservative). This composition was stored closed vessels and was found to be stable for at least 6 months. The paste was then applied on the affected area of skin.
EXAMPLE 8
Paste obtained in example 1 (8.0 g) is mixed with 5.0 g of glycerol, 0.6 g of beeswax and 1.0 g of triethanol amine as emulsifier, 1.0 g of vetiver oil (to give fragrance) and 0.2 g of methyl paraben (added as preservative). This composition was stored closed vessels and was found to be stable for at least 6 months.
EXAMPLE 9
The compositions given in example 1-8 and as a control only Indigofera tinctoria leaf powder was mixed with water were applied to the affected skin areas of various patients suffering from skin ailments such as dry skin, foot-cracking, scaling, eczema and fungal infections. The results, after application of the skin compositions, are summarized below.
EXAMPLE 9A
Treatment of Dry skin: The composition given in examples 1 to 8 was applied 1 or 2 times a day on the affected area of dry skin on patient for 3 to 4 days.
The results are tabulated in Table 1: Table 1
It was observed that the dry skin condition was completely cured and natural and supple skin were found to be restored on treating with the composition of Examples 1 to 8.
Example 9B
Treatment of Foot cracking: The affected foot was thoroughly cleaned with soap and soaked in lukewarm salt water for about 15 minutes and allowed to dry. Then the composition given in example 1 to 8 was applied in the affected areas of the foot and some of the surrounding areas for 3-4 consecutive days. Then the foot was kept undisturbed for 30 to 60 minutes.
It was observed that after the application of the medicine for 3 to 4 consecutive days, the dry and thickened skin was found to be completely removed. The Figure 1 shows the before and after images of foot cracking upon applying the composition. The natural and supple skin was restored and foot crack did not recur at least for one year upon treating with composition of
Example 1-8
EXAMPLE 9C
Treatment of Scaling: The composition given in examples 1-8 were applied to the affected areas of the foot of the patient 2 times per day for one week. The results are tabulated in Table 3:
It was observed that the flakes sticking to the skin were peeled off. The itching and redness were completely healed and smooth skin appeared within 3-4 days upon treating with the compositions of Example 1-8. EXAMPLE 9D
Treatment of Eczema: The composition, given in examples 1-8, were applied to the affected area of skin of the patient 2 times per day for 2-3 days.
The results are tabulated in Table 4:
The Figure 2(a) is a photograph of an Eczema patient with severe red rashes, bumps, scales on the back of the neck before applying the composition and Fig 2(b) is the photograph of the skin after applying the composition on the affected area 2 times per day for 2-3 days. It was observed that the itching, red rashes, bumps on the skin and scaly, leathery patches of skin associated with eczema were found to be cured and natural and supple skin was restored upon application of the composition in Examples 1-8.
EXAMPLE 9E
Treatment of Fungal infection: The composition given in examples 1-8 were applied to the affected area of skin, showing the characteristics of tinea infections, two times per day for 3-4 days.
The results are tabulated in Table 5:
It was observed that the compositions of Examples 1-8 were effective in reducing the itching, redness, scaling and the inflammation associated with the tinea infections. The Figure 3(a) and 3(b) shows the photographs before and after applying the composition on a patient with fungal infections respectively.
The paste of dried indogofera leaves with water alone (without bases such as Cao, MgO) was found not found to be effective for treating any of the above skin ailments. Hence combining indigofera leaves powder with water and bases selected from MgO, CaO, SrO, BaO, Li2O, Na2O, K2O, Rb2O, Cs2O, LiOH, NaOH, KOH, RbOH, CsOH, Li2CO3, Na2CO3, K2CO3, Rb2CO3 and Cs2CO3 provides distinct advantages in treating skin disorders such as fungal, scaling, foot-crack, eczema and dry skin diseases. A very fast and permanent/long term cure was observed. The compositions may also be useful in treating other skin disorders like psoriasis, foot com disease.
The foregoing description of specific embodiments of the present invention has been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the present invention to the precise forms disclosed, and obviously many modifications and variations are possible in light of the above teaching.
The embodiments were chosen and described in order to best explain the principles of the present invention and its practical application, to thereby enable others, skilled in the art to best utilize the present invention and various embodiments with various modifications as are suited to the particular use contemplated.
It is understood that various omission and substitutions of equivalents are contemplated as circumstance may suggest or render expedient, but such are intended to cover the application or implementation without departing from the spirit or scope of the present invention.
Claims
1. A topical herbal composition comprising: a. 1 to 5 parts by weight of a mixture comprising 80 wt% to 99.9 wt% of dried Indigofera tinctoria leaves powder or aqueous extract and 0.1wt% to 20 wt% of a base or a mixture of two or more bases, and b. 1 to 10 parts by weight of water.
2. The topical herbal composition as claimed in claim 1, wherein the base(s) is/are selected from the group comprising of CaO, MgO, SrO, BaO, Li2O, Na2O, K2O, Rb2O, Cs2O, LiOH, NaOH, KOH, RbOH, CsOH, Li2CO3, Na2CO3, K2CO3, Rb2CO3 and Cs2CO3.
3. The topical herbal composition as claimed in claim 1, wherein the composition further comprises 10 wt% to 40 wt% of a pharmaceutically acceptable excipient, 0.01wt%- 0.3 wt% of a preservative, 0.1wt% to lwt% of a fragrance oil, and 3 wt% to 8 wt% of an emulsifying agent.
4. The topical herbal composition as claimed in claim 1, wherein the pharmaceutically acceptable excipient is selected from glycerol, petroleum jelly, or beeswax, the preservative is selected from methyl paraben, butylparaben, ethylparaben, or propylparaben and the fragrance oil is selected from vetiver oil, lavender oil, lemongrass oil, jasmine, or sandalwood oil and the emulsifying agent is selected from triethanol amine, beeswax, borax, lecithin, gum arabic, gelatin, or cholesterol.
5. The topical herbal composition as claimed in claim 1, wherein the composition is an ointment, a paste, or a cream.
6. The topical herbal composition as claimed in claims 1 to 5, wherein the composition comprises: a. 2.5 parts by weight of the mixture of dried Indigofera tinctoria leaves powder or aqueous extract and CaO powder in a weight ratio of 97.5:2.5, and b. 5.5 parts by weight of water.
7. The topical herbal composition as claimed in claim 6, wherein the composition further comprises 3.0 wt% of glycerol, 1.0 wt% of vetiver oil and 0.1 wt% of methyl paraben.
8. The topical herbal composition as claimed in claim 1 for treatment of skin ailments selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like.
9. A method of treating skin ailments selected from dry skin, foot-cracking, eczema, scaling, fungal infections, psoriasis, foot com disease or the like by applying the composition as claimed in claims 1 to 5 on the affected area for 3 to 5 days.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202241013179 | 2022-03-10 | ||
IN202241013179 | 2022-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023170714A1 true WO2023170714A1 (en) | 2023-09-14 |
Family
ID=87936321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2023/050232 WO2023170714A1 (en) | 2022-03-10 | 2023-03-10 | A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023170714A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016162484A1 (en) * | 2015-04-09 | 2016-10-13 | Galderma Sa | An extract from indigo naturalis and a process for preparing the same |
KR20220044435A (en) * | 2019-05-03 | 2022-04-08 | 아조라 테라퓨틱스 인코포레이티드 | Compositions comprising indigo and/or indigo derivatives and methods of using the same |
-
2023
- 2023-03-10 WO PCT/IN2023/050232 patent/WO2023170714A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016162484A1 (en) * | 2015-04-09 | 2016-10-13 | Galderma Sa | An extract from indigo naturalis and a process for preparing the same |
KR20220044435A (en) * | 2019-05-03 | 2022-04-08 | 아조라 테라퓨틱스 인코포레이티드 | Compositions comprising indigo and/or indigo derivatives and methods of using the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10596148B2 (en) | Topical compositions for treatment of psoriasis | |
JPH03501605A (en) | Compositions for the treatment of hemorrhoids and others | |
US20050214244A1 (en) | Menopause homeopathic formulations | |
JP2000143507A (en) | External preparation containing capsaicin | |
US20050013871A1 (en) | Pharmaceutical composition for the treatment of itch | |
EP1335719B1 (en) | Cetyl myristate and cetyl palmitate for treating eczema and/or psoriasis | |
AU2001260833A1 (en) | Treating eczema and/or psoriasis | |
US8586064B2 (en) | Treating eczema and/or psoriasis | |
EP2343038B1 (en) | Dermatological compositions comprising a combination of peroxidized lipids and zinc for use amongst others in the treatment of herpes. | |
WO2023170714A1 (en) | A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases | |
EP1083914B1 (en) | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions | |
AU2007200216A1 (en) | Skin formulation usable as a therapeutic application for the treatment of general skin disorders and a method of preparation thereof | |
US20050214243A1 (en) | Feminine homeopathic formulations | |
Kocsard | Three cases of exudative chronic discoid and lichenoid dermatosis (Sulzberger and Garbe)(in Shanghai) | |
Badr et al. | Boswellia serrata Roxb., Boswellia carteri Birdw. | |
WO2023094899A1 (en) | Skin therapeutic composition | |
RU2200024C2 (en) | Biologically active composition of balsamic ointment "panatseya" | |
WO2024073013A1 (en) | Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation | |
WO2024073011A1 (en) | Topical compositions and methods for the treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation | |
Clyman | Comparative effects of hydrocortisone and hydrocortisone-coal tar extract creams in cases of atopic dermatitis | |
CN108235683A (en) | A kind of traditional Chinese herb medicine for being used to treat allergic dermatitis | |
NZ522434A (en) | Treating eczema and/or psoriasis | |
Assessment | Skin Conditions I | |
HU208489B (en) | Process for producing pharmaco-cosmetical ointment for treating vein diseases, tissue ecchymoses, strains, other inflammatoric processes and shin-ulcer | |
JPS62298535A (en) | Dermatic drug for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23766284 Country of ref document: EP Kind code of ref document: A1 |